期刊文献+

一例全身型幼年特发性关节炎并发巨噬细胞活化综合征的主要诊断及编码探讨

Discussion of the Main Diagnosis and Encoding of a Case of Systemic Juvenile Idiopathic Arthritis Complicated with Macrophage Activation Syndrome
原文传递
导出
摘要 全身型幼年特发性关节炎的部分患儿在病程中可并发巨噬细胞活化综合征,而巨噬细胞活化综合征会造成全身多器官损伤。通过阐述一例全身型幼年特发性关节炎并发巨噬细胞活化综合征病例的主要诊断选择及编码查找的过程,进而探讨疑难病例主要诊断的正确选择及编码的查找。本病例虽然巨噬细胞活化综合征只是全身型幼年特发性关节炎的一个并发症,但是全身型幼年特发性关节炎并不致死,而患儿发生巨噬细胞活化综合征的病情却十分危重,所以应选择巨噬细胞活化综合征为主要诊断,ICD-10编码D76.1,全身型幼年特发性关节炎为其他诊断,ICD-10编码M08.2。 Macrophage activation syndrome may occur in the course of the disease in some children with systemic juvenile idiopathic arthritis, macrophage activation syndrome can cause multiple organ damage in the whole body. The author expounds on a case of systemic juvenile idiopathic arthritis concurrent macrophage activation comprehensive syndrome were mainly diagnosed and code searching process, and then discuss the correct choice of the main diagnosis of difficult cases and encoding search. In this case, although the macrophage activation syndrome is systemic juvenile idiopathic arthritis a complication, but systemic juvenile idiopathic arthritis is not lethal, while the children of macrophages activation syndrome, the condition is very critical, so this case should select the "macrophage activation syndrome" as the main diagnosis and ICD-10 coding D76.1."systemic juvenile idiopathic arthritis"for other diagnostic and ICD-10 coding M08.2.
出处 《中国病案》 2016年第6期26-28,共3页 Chinese Medical Record
关键词 全身型幼年特发性关节炎 巨噬细胞活化综合征 主要诊断 编码 Systemic juvenile idiopathic arthritis Macrophage activation syndrome main diagnosis Code
  • 相关文献

参考文献8

  • 1何晓琥.幼年特发性关节炎——国际风湿病学会联盟新分类标准讨论稿[J].中华儿科杂志,2002,40(4):254-255. 被引量:79
  • 2Ramanan AV. Rosenblunl ND, Feldman BM, et 01. Favorable outcome in patientl with renal intolvenmnt conqdicating macrophage activatima syndrome in systemic : onset Juvenile rheumatoidarthritis[J]. Rheumatol, 2004. 31 (10) :2068-2070.
  • 3金燕樑.全身型幼年特发性关节炎研究进展[J].临床儿科杂志,2011,29(11):1097-1100. 被引量:7
  • 4Ramanan AV. Rosenblum ND, Feldman BM. et al. Favorable outcome in patients with renal involvement complicating macro-phage activation syndrome in stystemic onset juvenile rheumatoid arthritis[J]. Rheumatol, 2004, 31 (10) :2068-2070.
  • 5Parodi A, Dsvi S, Pringe AB, eg. Macrophage activation syndrome in juvenile systemic lupus erythematosus : a multi- national muhieenter study of thiay eight patients[J]. Artlnitis Rheum, 2009, 60 (11) : 3388-3399.
  • 6Alino GA, Manlhict c, Yeung RS, et d. Macrohpage activation syndrome in the acute phase of Kawasaki disease[J]. Pediatrhemat01 Oncel, 2010, 32 (7) : 527-531.
  • 7Zur stadt U, Beutel K, kolberg S, et al. Mutation spectrum In children with primary hemophagoeyticly phohistiocytosis: mole-cular and functional analyses of PRF1, UNC13D, STX11, and RAB27A[J]. Hum Mutat, 2006, 27:62-68.
  • 8刘爱民,主编.医院管理学病案管理分册[M].北京:人民卫生出版社,2012,5.

二级参考文献34

  • 1Kotto-Kome AC, Fox SE, Lu W, et al. Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharalacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model [J]. Pharrnaeol Res,2004,50(1):55-58.
  • 2Hawkins PN, Laehmann HJ, Aganna E, et al. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra [J ]. Arthritis Rheum,2004,50(2) :607-612.
  • 3Hoffman HM, Rosengren S, Boyle DL, et ol. Prevention of coldassociated acute inflammation in familial cold autoinflammatory syndrome by interleakin-1 receptor antagonist [J]. Lancet,2004, 364(9447) : 1779-1785.
  • 4Gattorno M, Tassi S, Carta S, et ol. Pattern of interleukin-1β secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIASI mutations [J]. Arthritis Rheum,2007,56(9) :3138-3148.
  • 5Shemon AN, Sluyter R, Fernanc]o SL, el al. A ThP57 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-indueed mycobacterial killing by macrophages [J]. J Biol Chem, 2006,281 (4) : 2079-2086.
  • 6Jelusic M, Lukid IK, Tambi6-Bukovac L, et ol. Interleukin-18 as a mediator of systemie juvenile idiopathic arthritis [J]. Clin Rheu-matol, 2007,26 (8) : 1332-1334.
  • 7Lotito AP, Campa A, Silva CA, et al. Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis [ J 1. J Rheumatol, 2007,34 (4) : 823-830.
  • 8DinareIlo CA. The many worlds of reducing interleukin-1 [J]. Arth- ritis Rheum, 2005,52(7) : 1960-1967.
  • 9Herlin T. Tocilizumah: the evidence for its place in the treatment of juvenile idiopathic arlhritis [ J ]. Core Evid, 2009,4 : 181 - 189.
  • 10Murakami M, Hibi M, Nakagawa N, et al. IL-6 induced homo- dimerization of gpl30 and associated activation of a tyrosine kinase [J]. Science, 1993,260(5115) : 1808-1810.

共引文献86

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部